Stay Updated: Posts | Comments

«
»

  • VRM: Gardasil, Hepatitis B vaccine Recombivax & Merck scandal – Dangers of Amorphous Aluminum Hydroxyphosphate Sulfate adjuvant

    Vaccine Info
    26th January 2020 - By Joel Lord

    What are ordinary families fighting for? Simply put, the freedom to determine the health choices for their children unencumbered by Government decision-making and self-serving Corporations, the freedom to acquire access to accurate, unbiased scientific knowledge on vaccine safety and efficacy, and the freedom to decide for themselves whether or not to comply with vaccination, without sacrificing parental autonomy in doing so. Parents are fed up with being brow-beaten and condescended to by so-called health experts, who are  frequently shown to have serious conflicts of interest, with direct financial ties to the vaccine industry. Science has been manipulated to convince the public that vaccines are strictly essential.

    Every vaccine violates informed consent, because every vaccine is an experiment. Vaccines are not being tested to determine the long-term effects of compound synergy or in terms of contraindication of adverse ingredients contained in a vial. Manufacturers, by their own admission listed on every package monograph, admit that vaccines have not been scrutinized for carcinogenic or mutagenic potential, or their potential to impair fertility. This is relevant because children and young adults are being irreparably harmed by vaccines, and their parents have no recourse to pinpoint the exact cause of the infraction, since vaccine companies have not done their due diligence in responsibly investigating the hazards of their product before subjecting it on the community at large. They haven’t even come close. Instead, they have used our children as surrogate guinea pigs and allowed post-marketing surveillance to be the determinate measuring stick after the damage ensues. Safety is not a prerequisite for them. The bottom line is greed, forever meeting the desired annual profit margin regardless of the method.

    The clinical trial data on vaccines is clouded by faulty science and fraught with inconsistencies. Negative results are easily glossed over using the exclusive regulatory system of reference known as relative risk assessment. Numbers are altered to meet the target by simply shifting the parameters of the study and removing any obstacles potentially obstructing licensing. “Scientific” papers purporting to be genuine have presented misleading data, while glossing over negative trial results to market vaccine products. Vaccine manufacturers have purposefully rigged their control studies often using placebos containing aluminum, which are designed to be reactive, rather than utilizing a benign substance like saline, to maintain a perception of positive results.

    For instance, Merck, the manufacturer of the HPV vaccine Gardasil, actually used AAHS or amorphous aluminum hydroxyphosphate sulfate in place of an “inert” placebo, which was injected into the control group of volunteers. The remaining group was given the Gardasil vaccine. The tabulated results showed a comparable level of serious adverse events (SAE), nervous system disorders reaching 681 (5.8%) in the Gardasil group and 495 (5.1%) in the Placebo group, including 39 (0.4%) vascular disorders, 2% higher than seen that of the Gardasil group. ‘102 subjects who received Gardasil and 99 subjects who received Placebo developed an SAE during the course of the study…there were 136 events in the Gardasil group and 125 events in the placebo group. One subject may have had more than one SAE. Some events were noted twice in the same subject, or a number of events in one subject were related to one major event, so these were combined into one event during review. Thus, the totals are 116 events in the Gardasil group and 115 events in the placebo group.‘
    This practice of leveling the scales, removing whichever obstacles are seen as an impediment by watering down the control group parameters and stacking the field with compromised test-subjects contravenes the fundamental principles of scientific inquiry.
    The conclusions of the Gardasil trial created the perception that the stability of the vaccine itself was secure. ‘In females 9-26 years of age, Gardasil, when administered in a 3 dose regimen at 0, 2, and 6 months appeared to produce comparable adverse event profiles in those who received placebo (alum and and saline) with a few exceptions. There was a somewhat higher proportion of Gardasil recipients as compared to placebo recipients with an injection site adverse event in the 5 days after any vaccination, and there was a somewhat higher proportion of Gardasil recipients with a complaint that was moderate or severe as compared to placebo recipients…There was a comparable proportion of subjects in each group with a systemic adverse event in the 15 days after any vaccination…New medical conditions in the vaccination period and post-month 7 period were generally balanced between the treatment groups. There were a small number of subjects who developed a new autoimmune disorder ithe vaccine and placebo group. A majority of the subjects who developed such illnesses had pre-vaccination symptoms of joint pain, and incidence of rates of specific autoimmune diseases noted in these studies were, in general, not higher than the incidence rates reported in the literature. However, there were a few subjects without previous symptoms.‘
    ‘There were 10 deaths in the Gardasil recipients (0.8%), and 7 deaths in the placebo group (0.7%). The majority of the deaths were due to trauma in both groups. These deaths did not appear related to vaccine administration. In each treatment group, there was a death related to a deep vein thrombosis and/or pulmonary embolism, and both subjects were on hormonal contraceptives. The Gardasil recipient with this event had symptoms of leg pain prior to the first vaccination. The other Gardasil recipients who died included one subject with pancreatic cancer 578 days after dose 3, and one young male who died of arrhythmia 27 days after dose 1. This latter subject had a strong family history for arrhythmia. These events did not appear related to administration of the vaccine.’  Excerpt – Section 10.3.1 Deaths
    In the follow-up clinical trials on males, the tabulated tables demonstrated a higher rate of nervous system disorders occurring in the placebo group, 138 as compared to 121 vaccine-related adverse experiences in the Gardasil group. By utilizing the relative risk ratio model measuring strictly the vaccine vs. placebo, a standard practice in the vaccine industry which is fully endorsed by the FDA, researchers conducting the study framed the vaccine as comparatively safe. Males have been dying from arrhythmia after getting the Gardasil vaccine. Therefore, the official package insert data reflected the skewed statistics, which, to this day, has portrayed the HPV vaccine Gardasil as innocuous for both sexes. This method of analysis is no less fraudulent than insider trading deals on the stock market. It proves absolutely nothing about the safety and efficacy of the vaccine, a far cry from serious scientific inquiry. On the contrary, it disguises the actual statistics and protects the manufacturer from future liability. Subsequently, Gardasil has been linked to multi-focal demyelinating syndromes like Multiple Sclerosis, a devastating nervous system disorder. Lives have been lost and promising futures have been completely derailed due to the circulation of fraudulent clinical studies. Vaccines must be tested using a straightforward and transparent system, applying the model known as absolute risk which shows clear-cut hazards caused by a vaccine, charting the accumulative neurological effects in the aftermath of an injection. Also the parameters of adverse reactions needs to be expanded to encompass latent injuries surfacing within 6 months to a year, including concomitant symptoms resulting from additional vaccines. Vaccine companies must be held accountable for presenting their findings transparently, without any doctoring, exaggeration or misrepresentation in any way. Parents are repeatedly told the risks accorded to vaccines are negligible. This misleading practice is not only professionally disingenuous but dangerous to young children.

    My new book Keep Them From Harm addresses many tough questions and draws back the curtain to reveal the underlying flaws which justify and support the vaccine industry. I have devoted an entire chapter to uncovering the Gardasil deception. 

    As an adjuvant, amorphous aluminum hydroxyphosphate sulfate is shown to have an an “enhanced binding capacity,” rendering it much more powerful than either aluminum phosphate or aluminum hydroxide. ‘Merck Aluminum Adjuvant (AAHS) is a proprietary aluminum hydroxyphosphate sulfate formulation that is both physically and functionally distinct from traditional aluminum phosphate and aluminum hydroxide adjuvants. At a macromolecular level, AAHS is structurally related to aluminum phosphate as it forms an amorphous mesh‑like structure. AAHS bears a nearly zero charge at neutral pH. In contrast, aluminum hydroxide adjuvants form highly crystalline structures. These structural differences might potentially impact the ability of an adjuvant to form an antigen depot as well as its intrinsic capacity to stimulate antigen presenting cells.‘ In reference to the Gardasil vaccine, the ‘virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18‘ are literally fixed onto the aluminum and redistributed ubiquitously throughout the body.

     
    A 2002 article in the publication ‘Vaccine’ revealed that ‘The area under the blood level curve for 28 days indicated that three times more aluminum was absorbed from aluminum phosphate adjuvant than aluminum hydroxide adjuvant.’ However, it also purported  that  ‘The in vitro dissolution and in vivo absorption studies indicate that aluminum-containing adjuvants which are administered intramuscularly are dissolved by alpha-hydroxycarboxylic acids in interstitial fluid, absorbed into the blood, distributed to tissues, and eliminated in the urine.’ This finding is misleading, and has been refuted in countless peer-reviewed studies which demonstrate that aluminum adjuvant from vaccines is not being sequestered and chelated from the body. Rather, the aluminum bio-accumulates in organs, and is reaching the confines of the brain, rapidly wreaking havoc on the central nervous system. In the seminal book The HPV Vaccine On Trial: Seeking Justice For A Generation Betrayed, the authors describe the precise mechanism where-by the AAHS transgresses the blood-brain barrier in the vaccine recipient: ‘Macrophages can engulf injected nanoparticles of the adjuvant and carry them accross the blood-brain barrier, inciting inflammatory responses and a cascade of neurological and other effects… “an immune system bonfire.”’  The pathway, for AAHS is not specifically bio-electric incurring a breach of the electrical grid system, as occurs with Aluminum hydroxide adjuvant in other vaccines. ‘AAHS bears a nearly zero charge at neutral pH, whereas both aluminum phosphate and aluminum hydroxide are strongly charged at neutral pH. The net charge of these two adjuvants likely impacts both their ability to bind antigen as well as the release of that antigen following injection into the host and exposure to serum fluids which are likely to approximate a neutral pH.’ 

    The FDA reaffirmed its commitment to Gardasil in 2009, 3 years after Merck was formally grated its license on the vaccine on June 6, 2006. ‘FDA also analyzes adverse events (possible side effects) associated with individual lots to look for any unusual patterns. No such patterns have been observed in FDA’s review of HPV vaccine lots since the vaccine was licensed…Given the large number of doses distributed, it is expected that, by chance alone, serious adverse events and some deaths will be reported in this large population during the time period following vaccinations. Our monitoring and analysis of reports, including in-depth medical review, statistical data mining techniques, and analysis of reporting rates (number of adverse events/number of doses distributed)  are designed to detect serious events that occur at rates greater than expected…Concerns have been raised about reports of deaths occurring in individuals after receiving Gardasil. As of December 31, 2008, 32 deaths had been reported to VAERS. There was not a common pattern to the deaths that would suggest they were caused by the vaccine. In the majority of cases with available autopsy, death certificate and medical records, the cause of death was explained by factors other than the vaccine.’ Once again, application of the relative risk ratio disguises and ignores the real statistics. Causality is routinely shifted to supposed mitigating co-factors other than the vaccine, or thoroughly watered down by overall percentages which is scientifically disingenuous and medically irresponsible. Individual reactions matter, and minimal protocols have not been met to justify the statements being made by regulators in the field. By ignoring the properties of the vaccine in analysis of neuropathy and any correlation of the injuries to the timing of the injection, the medical establishment has discredited the entire realm of science and integrity of science-based inquiry. Thereby, they are implicated in the same cover-up being perpetrated by the vaccine industry.

    The FDA rubber stamp of approval sets a dangerous precedent which places the safety of young women in jeopardy at the behest of the industry bottom line sales quota. ‘Based on the review of available information by FDA and CDC, Gardasil continues to be safe and effective, and its benefits continue to outweigh its risks.’ A cross-section of post marketing experience listed on the Gardasil package insert reveals the vaccine is neither safe nor effective. In fact, the myriad of health risks posed by the vaccine are quite overwhelming.

    ‘The following adverse events have been spontaneously reported during post-approval use of GARDASIL:
    Blood and lymphatic system disorders: Autoimmune hemolytic anemia, lymphadenopathy.
    Respiratory, thoracic and mediastinal disorders: pulmonary embolus.
    Gastrointestinal disorders: Nausea, pancreatitis, vomiting.
    General disorders and administration site conditions: Asthenia, chills, death, fatigue, malaise.
    Immune system disorders: Autoimmune diseases, hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm, and urticaria.
    Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
    Nervous system disorders: Dizziness, Guillain-Barré syndrome, headache, motor neuron disease, paralysis, seizures, syncope (including syncope associated with tonic-clonic movements and other seizure-like activity) sometimes resulting in falling with injury, transverse myelitis.
    Vascular Disorders: Deep venous thrombosis.’ Excerpt from Gardasil package insert

    Both Gardasil AND the Hepatitis B vaccine, Recombivax and have been linked to manifestations resembling Multiple Sclerosis. The common toxin found in each shot is Amorphous Aluminum Hydroxyphosphate Sulfate or AAHS. The gap in years between the administering of these vaccines spans a minimum of 9 years, during which time a child is subjected to multiple vaccines containing aluminum adjuvants, however the specific targeting of the nervous system by the formulation AAHS stands apart for its severity, which is devastating, setting the stage for neuro-developmental dysfunction and neurological impairment often leading to Autism at 12-18 months and the crippling symptoms of MS in the teenage years. There have been 45,777 incidence of “Nervous system disorders” officially linked to Gardasil, and at least 31,131 such incidence tied specifically to the Hepatitis B vaccine Recombivax. This is extremely crucial information as it reveals the preliminary data used to promote either vaccine was incomplete, in fact it was deliberately erroneous. The placebo used in the Gardasil trials, which contained AAHS by design, had elicited immediate adverse nervous system responses in the recipients, the results of which were used to overshadow and cancel out the toxic reactions to the vaccine. Only the placebo effect was highlighted in the subsequent marketing report, which enabled Merck to claim the vaccine had not revealed any substantial nervous system disorders. Post-marketing surveillance tells a very different story, and clearly demonstrates a pattern of neurological upheaval occurring in the aftermath of Gardasil and Recombivax injections. Most of the symptoms exhibited on this extensive list are chronic and debilitating, requiring continued surveillance and therapy for the remainder of the individual’s life.

    Gardasil – Tally of adverse reactions accumulated since the commercial release of the Gardasil vaccine onto the market:
    Headache (15863)

    Dizziness (13682)

    Syncope (10337)

    Loss of consciousness (4301)

    Seizure (3368)

    Hypoaesthesia (3132)

    Paraesthesia (2960)

    Tremor (2230)

    Presyncope (2116)

    Disturbance in attention (1471)

    Lethargy (1257)

    Migraine (1177)

    Dyskinesia (1174)

    Somnolence (1160)

    Memory impairment (1056)

    Sensory disturbance (771)

    Cognitive disorder (713)

    Unresponsive to stimuli (666)

    Paralysis (519)

    Epilepsy (508)

    Hypersomnia (500)

    Generalised tonic-clonic seizure (495)

    Orthostatic intolerance (461)

    Facial paralysis (459)

    Amnesia (453)

    Depressed level of consciousness (429)

    Multiple sclerosis (417)

    Speech disorder (414)

    Guillain-Barre syndrome (392)

    Burning sensation (380)

    Balance disorder (374)

    Hypotonia (368)

    Neuropathy peripheral (348)

    Dizziness postural (339)

    Neuralgia (333)

    Autonomic nervous system imbalance (331)

    Tonic clonic movements (323)

    Dysstasia (294)

    Paraparesis (280)

    Movement disorder (268)

    Nervous system disorder (265)

    Altered state of consciousness (255)

    Mental impairment (245)

    Dysarthria (238)

    Sensory loss (238)

    Complex regional pain syndrome (232)

    Optic neuritis (231)

    Seizure like phenomena (229)

    Hyperaesthesia (223)

    Monoplegia (205)

    Aphasia (196)

    Facial paresis (163)

    Narcolepsy (163)

    Hypokinesia (155)

    Neurological symptom (144)

    Demyelination (141)

    Hemiparesis (140)

    Visual field defect (139)

    Acute disseminated encephalomyelitis (137)

    Myoclonus (136)

    Muscle contractions involuntary (135)

    Ataxia (134)

    Diplegia (134)

    Dysaesthesia (133)

    Hemiplegia (126)

    Motor dysfunction (124)

    Dysgeusia (123)

    Poor quality sleep (123)

    Petit mal epilepsy (114)

    Encephalopathy (110)

    Areflexia (98)

    Coordination abnormal (98)

    Myelitis transverse (97)

    Paresis (97)

    Head discomfort (96)

    Parosmia (96)

    Tension headache (92)

    Monoparesis (91)

    Clonus (89)

    Postictal state (84)

    Hypertonia (83)

    Cerebrovascular accident (81)

    Cataplexy (80)

    Tonic convulsion (78)

    Restless legs syndrome (74)

    Central nervous system lesion (73)

    Migraine with aura (73)

    Hyporeflexia (70)

    Nystagmus (70)

    Psychomotor hyperactivity (69)

    Tongue biting (67)

    Drooling (66)

    Partial seizures (63)

    Coma (60)

    		 Dysgraphia (60)

    Hyperreflexia (59)

    Polyneuropathy (56)

    Meningism (55)

    Formication (51)

    Allodynia (50)

    Dystonia (48)

    Autonomic neuropathy (47)

    Tunnel vision (47)

    Incoherent (46)

    Myasthenia gravis (46)

    Encephalitis autoimmune (43)

    Brain oedema (42)

    Opisthotonus (42)

    Quadriplegia (42)

    Idiopathic intracranial hypertension (41)

    Central nervous system inflammation (37)

    Cerebral hypoperfusion (37)

    Hyporesponsive to stimuli (37)

    Peroneal nerve palsy (37)

    Clonic convulsion (36)

    Dyscalculia (36)

    Intracranial pressure increased (36)

    Autoimmune encephalopathy (35)

    Slow response to stimuli (35)

    Neuritis (34)

    Psychogenic seizure (33)

    Consciousness fluctuating (31)

    Radiculopathy (31)

    Status epilepticus (31)

    Atonic seizures (29)

    Focal dyscognitive seizures (29)

    Clumsiness (28)

    Myoclonic epilepsy (28)

    Cerebral infarction (27)

    Hypotonic-hyporesponsive episode (27)

    Paraplegia (27)

    Sudden onset of sleep (27)

    Asterixis (26)

    Brain injury (26)

    Taste disorder (26)

    Radiculitis brachial (25)

    Cerebral disorder (24)

    Cerebral haemorrhage (24)

    Sensorimotor disorder (24)

    White matter lesion (23)

    Extensor plantar response (22)

    Cerebellar syndrome (21)

    Cluster headache (21)

    Neuromyelitis optica spectrum disorder (21)

    Noninfective encephalitis (21)

    Sinus headache (21)

    Brachial plexopathy (20)

    Facial spasm (20)

    Juvenile myoclonic epilepsy (20)

    Pleocytosis (20)

    Prosopagnosia (20)

    Sleep paralysis (20)

    Chronic inflammatory demyelinating polyradiculoneuropathy (19)

    Miller Fisher syndrome (19)

    Neuralgic amyotrophy (19)

    Aura (18)

    Cerebellar ataxia (18)

    Hyperpathia (18)

    Language disorder (18)

    Muscle spasticity (18)

    Small fibre neuropathy (18)

    Dementia (17)

    Febrile convulsion (17)

    Multiple sclerosis relapse (17)

    Retrograde amnesia (17)

    Slow speech (17)

    Transient ischaemic attack (17)

    Amyotrophic lateral sclerosis (16)

    Carpal tunnel syndrome (16)

    Hemianopia (16)

    Central nervous system vasculitis (15)

    Chorea (15)

    Leukoencephalomyelitis (15)

    Basilar migraine (14)

    Cerebral venous sinus thrombosis (14)

    Judgement impaired (14)

    Quadriparesis (14)

    Ageusia (13)

    Cerebral atrophy (13)

    Dizziness exertional (13)

    Radial nerve palsy (13)

    Spinal cord disorder (13)

    Cranial nerve disorder (12)

    Meningeal disorder (12)

    Migraine without aura (12)

    Stupor (12)

    		 Subarachnoid haemorrhage (12)

    Tongue paralysis (12)

    Neuromyopathy (11)

    Reflexes abnormal (11)

    Cerebral cyst (10)

    Drop attacks (10)

    Encephalitis post immunisation (10)

    Essential tremor (10)

    Fine motor skill dysfunction (10)

    Head titubation (10)

    Peripheral paralysis (10)

    Sciatica (10)

    Cervical radiculopathy (9)

    Cervicobrachial syndrome (9)

    Circadian rhythm sleep disorder (9)

    IIIrd nerve paralysis (9)

    New daily persistent headache (9)

    Psychomotor skills impaired (9)

    Relapsing-remitting multiple sclerosis (9)

    Repetitive speech (9)

    Temporal lobe epilepsy (9)

    Thoracic outlet syndrome (9)

    Akinesia (8)

    Anaesthesia (8)

    Arachnoid cyst (8)

    Central pain syndrome (8)

    Cerebral artery occlusion (8)

    Cerebrovascular disorder (8)

    Decreased vibratory sense (8)

    Demyelinating polyneuropathy (8)

    Irregular sleep wake rhythm disorder (8)

    IVth nerve paralysis (8)

    Lhermitte’s sign (8)

    Motor neurone disease (8)

    Peripheral sensory neuropathy (8)

    Spinal cord oedema (8)

    Trigeminal neuralgia (8)

    VIth nerve paralysis (8)

    Anosmia (7)

    Cerebral venous thrombosis (7)

    Dreamy state (7)

    Dyslalia (7)

    Hemiplegic migraine (7)

    Hydrocephalus (7)

    Hyperkinesia (7)

    Hypogeusia (7)

    Hypoxic-ischaemic encephalopathy (7)

    Intellectual disability (7)

    Ischaemic stroke (7)

    Mononeuritis (7)

    Peripheral nerve lesion (7)

    Post herpetic neuralgia (7)

    Pyramidal tract syndrome (7)

    Tardive dyskinesia (7)

    Axonal neuropathy (6)

    Blood brain barrier defect (6)

    Dyslexia (6)

    Dyspraxia (6)

    Gliosis (6)

    Haemorrhage intracranial (6)

    Leukoencephalopathy (6)

    Neurodegenerative disorder (6)

    Occipital neuralgia (6)

    Apallic syndrome (5)

    Autoimmune neuropathy (5)

    Brain stem syndrome (5)

    Cerebral ventricle dilatation (5)

    Facial neuralgia (5)

    Freezing phenomenon (5)

    Hemianopia homonymous (5)

    Lower motor neurone lesion (5)

    Near death experience (5)

    Nerve compression (5)

    Neurological decompensation (5)

    Partial seizures with secondary generalisation (5)

    Peripheral motor neuropathy (5)

    Sedation (5)

    Stiff person syndrome (5)

    Vascular headache (5)

    Agnosia (4)

    Akathisia (4)

    Apraxia (4)

    Autonomic seizure (4)

    Cerebral circulatory failure (4)

    Cerebral thrombosis (4)

    Cranial nerve paralysis (4)

    Dysmetria (4)

    Encephalomalacia (4)

    Exertional headache (4)

    Extrapyramidal disorder (4)

    Facial nerve disorder (4)

    Febrile infection-related epilepsy syndrome (4)

    Fine motor delay (4)

    Frontal lobe epilepsy (4)
    Hemiparaesthesia (4)

    Intention tremor (4)

    Lumbosacral radiculopathy (4)

    Moyamoya disease (4)

    Myelopathy (4)

    Parkinsonism (4)

    Pineal gland cyst (4)

    Reduced facial expression (4)

    Seizure anoxic (4)

    Vocal cord paralysis (4)

    Anterograde amnesia (3)

    Basal ganglia stroke (3)

    Bradykinesia (3)

    Brain stem stroke (3)

    Brown-Sequard syndrome (3)

    Cerebral ischaemia (3)

    Coma hepatic (3)

    Delayed sleep phase (3)

    Hypoglossal nerve paralysis (3)

    Idiopathic generalised epilepsy (3)

    IIIrd nerve paresis (3)

    Intercostal neuralgia (3)

    Intracranial aneurysm (3)

    Intracranial hypotension (3)

    Intraventricular haemorrhage (3)

    Meralgia paraesthetica (3)

    Myasthenic syndrome (3)

    Myotonia (3)

    Retinal migraine (3)

    Spinal cord infarction (3)

    Thermohyperaesthesia (3)

    Tonic posturing (3)

    Uhthoff’s phenomenon (3)

    Ulnar nerve palsy (3)

    Vagus nerve disorder (3)

    Acute haemorrhagic leukoencephalitis (2)

    Agraphia (2)

    Amimia (2)

    Athetosis (2)

    Benign rolandic epilepsy (2)

    Cauda equina syndrome (2)

    Cerebellar infarction (2)

    Cerebral vasoconstriction (2)

    Cerebrospinal fluid leakage (2)

    Choreoathetosis (2)

    Clinically isolated syndrome (2)

    Convulsions local (2)

    Convulsive threshold lowered (2)

    Cubital tunnel syndrome (2)

    Decerebrate posture (2)

    Exaggerated startle response (2)

    Femoral nerve palsy (2)

    Generalised non-convulsive epilepsy (2)

    Glossopharyngeal neuralgia (2)

    Grimacing (2)

    Hashimoto’s encephalopathy (2)

    Hemianaesthesia (2)

    Hippocampal sclerosis (2)

    Hypergeusia (2)

    Intracranial mass (2)

    neonatal (1)

    Lacunar infarction (1)

    Lateral medullary syndrome (1)

    Irlen syndrome (2)

    		 Loss of proprioception (2)

    Marburg’s variant multiple sclerosis (2)

    Medication overuse headache (2)

    Multifocal motor neuropathy (2)

    Neuritis cranial (2)

    Neuroleptic malignant syndrome (2)

    Paraesthesia mucosal (2)

    Periodic limb movement disorder (2)

    Peripheral nerve palsy (2)

    Peripheral nerve paresis (2)

    Postictal paralysis (2)

    Progressive bulbar palsy (2)

    Radicular pain (2)

    Ruptured cerebral aneurysm (2)

    Sensory processing disorder (2)

    Simple partial seizures (2)

    Speech disorder developmental (2)

    Spinal meningeal cyst (2)

    Spontaneous cerebrospinal fluid leak syndrome (2)

    Status migrainosus (2)

    Sydenham’s chorea (2)

    Thalamic infarction (2)

    Thermoanaesthesia (2)

    Thermohypoaesthesia (2)

    Transverse sinus thrombosis (2)

    Trigeminal nerve paresis (2)

    Typical aura without headache (2)

    Vasogenic cerebral oedema (2)

    Vibratory sense increased (2)

    Acalculia (1)

    Acquired syringomyelia (1)

    Acute motor-sensory axonal neuropathy (1)

    Acute polyneuropathy (1)

    Adrenergic syndrome (1)

    Alexia (1)

    Altered pitch perception (1)

    Amnestic disorder (1)

    Anterior interosseous syndrome (1)

    Atypical benign partial epilepsy (1)

    Auditory nerve disorder (1)

     

    Limbic encephalitis (1)

    Locked-in syndrome (1)

    Lumbar radiculopathy (1)

    Myasthenia gravis crisis (1)

    Nerve degeneration (1)

    Neurologic neglect syndrome (1)

    Neuromuscular blockade (1)

    Neuromyotonia (1)

    Neuropsychiatric lupus (1)

    Paralysis recurrent laryngeal nerve (1)

    Paresis cranial nerve (1)

    Peripheral sensorimotor neuropathy (1)

    Phantom limb syndrome (1)

    Phrenic nerve paralysis (1)

    Polyneuropathy idiopathic progressive (1)

    Poor sucking reflex (1)

    Ballismus (1)

    		 Band sensation (1)

    Basilar artery occlusion (1)

    Brain compression (1)

    Brain hypoxia (1)

    Brain midline shift (1)

    Brain stem infarction (1)

    Bulbar palsy (1)

    Burning feet syndrome (1)

    Burning sensation mucosal (1)

    Carotid artery aneurysm (1)

    Cerebellar artery occlusion (1)

    Cerebellar atrophy (1)

    Cerebral artery stenosis (1)

    Cerebral calcification (1)

    Cerebrosclerosis (1)

    Cervicogenic headache (1)

    Cholinergic syndrome (1)

    Cogwheel rigidity (1)

    Convulsion in childhood (1)

    Cramp-fasciculation syndrome (1)

    Decorticate posture (1)

    Dementia Alzheimer’s type (1)

    Developmental coordination disorder (1)

    Diabetic hyperglycaemic coma (1)

    Drug withdrawal convulsions (1)

    Drug withdrawal headache (1)

    Dysdiadochokinesis (1)

    Embolic stroke (1)

    Encephalitis allergic (1)

    Enlarged cerebral perivascular spaces (1)

    Epileptic aura (1)

    Fontanelle bulging (1)

    Fumbling (1)

    Gait spastic (1)

    Gross motor delay (1)

    Hand-eye coordination impaired (1)

    Harlequin syndrome (1)

    Hoffmann’s sign (1)

    Horner’s syndrome (1)

    Hydromyelia (1)

    Hypoglossal nerve disorder (1)

    Hyposmia (1)

    Idiopathic partial epilepsy (1)

    IIIrd nerve disorder (1)

    Intraventricular haemorrhage

    Postresuscitation encephalopathy (1)

    Resting tremor (1)

    Sciatic nerve neuropathy (1)

    Seizure cluster (1)

    Sensory integrative dysfunction (1)

    Serotonin syndrome (1)

    Sympathicotonia (1)

    Tarsal tunnel syndrome (1)

    Thoracic spinal cord paralysis (1)

    Toxic encephalopathy (1)

    Upper motor neurone lesion (1)

    Vascular encephalopathy (1)

    Vertebral artery occlusion (1)

    Vertigo CNS origin (1)

    Vestibular migraine (1)

    Visual pathway disorder (1)

    VIth nerve disorder (1)
    The clinical trials for Recombivax were equally insufficient, and modeled on the 1981 testing given in advance of the release of the Hepatitis B Vaccine Heptavax B in which “The placebo consisted of alum alone in the vaccine diluent.” Just as Merck had misrepresented the facts by using a dangerous placebo for marketing Gardasil, they applied the same chicanery in selling Recombivax to the public and grandfathered the product in. It is alarming that health departments and regulators have consistently allowed this trend to continue, which places the industry above our communities.

    Pharmaceutical. 1987.0782.02.

     Recombivax HB – Tally of adverse reactions accumulated since the commercial release of Recombivax onto the market:
    Headache (7322)

    Dizziness (5048)

    Paraesthesia (3503)

    Seizure (2785)

    Syncope (2080)

    Somnolence (1975)

    Multiple sclerosis (1920)

    Hypotonia (1501)

    Tremor (1405)

    Hypoaesthesia (1259)

    Hypokinesia (1054)

    Hypertonia (872)

    Stupor (792)

    Loss of consciousness (728)

    Lethargy (693)

    Neuropathy peripheral (674)

    Optic neuritis (573)

    Febrile convulsion (571)

    Myasthenic syndrome (567)

    Facial paralysis (484)

    Speech disorder (477)

    Hypotonic-hyporesponsive episode (476)

    Demyelination (430)

    Nervous system disorder (430)

    Paralysis (419)

    Migraine (360)

    Dyskinesia (353)

    Guillain-Barre syndrome (333)

    Balance disorder (325)

    Coordination abnormal (304)

    Unresponsive to stimuli (298)

    Disturbance in attention (269)

    Presyncope (267)

    Coma (253)

    Generalised tonic-clonic seizure (244)

    Amnesia (233)

    Memory impairment (225)

    Dysgeusia (220)

    Sensory disturbance (217)

    Neuritis (216)

    Depressed level of consciousness (197)

    Encephalopathy (189)

    Cognitive disorder (182)

    Neuralgia (178)

    Movement disorder (157)

    Hemiparesis (154)

    Intellectual disability (152)

    Burning sensation (151)

    Epilepsy (149)

    Paresis (137)

    Visual field defect (135)

    Nystagmus (129)

    Opisthotonus (125)

    Ataxia (121)

    Dysarthria (120)

    Aphasia (118)

    Cerebellar syndrome (110)

    Hyperaesthesia (110)

    Hyporeflexia (108)

    Dysaesthesia (105)

    Neurological symptom (102)

    Hyperreflexia (97)

    Motor dysfunction (95)

    Myoclonus (91)

    Meningism (87)

    Muscle contractions involuntary (87)

    Hypersomnia (82)

    Simple partial seizures (79)

    Psychomotor hyperactivity (76)

    Hemiplegia (75)

    Extensor plantar response (73)

    Polyneuropathy (73)

    Myelitis transverse (70)

    Speech disorder developmental (69)

    Altered state of consciousness (68)

    Brain oedema (63)

    Mental impairment (62)

    Poor quality sleep (60)

    Sensory loss (59)

    Cerebrovascular accident (58)

    Infantile spasms (53)

    Formication (51)

    Dysstasia (50)

    Seizure like phenomena (48)

    Clumsiness (46)

    Monoplegia (44)

    Multiple sclerosis relapse (44)

    Ageusia (43)

    Drooling (43)

    Facial paresis (43)

    Intracranial pressure increased (39)

    Myelopathy (39)

    Central nervous system lesion (38)

    Extrapyramidal disorder (37)

    Hyporesponsive to stimuli (37)

    Radiculopathy (37)

    Carpal tunnel syndrome (36)

    Dystonia (36)

    Hyperkinesia (35)

    Petit mal epilepsy (35)

    Pleocytosis (35)

    Status epilepticus (35)

    Muscle spasticity (34)

    Tonic convulsion (34)

    Acute disseminated encephalomyelitis (33)

    Areflexia (33)

    Clonus (31)

    Cerebellar ataxia (30)

    Cerebral haemorrhage (30)

    Head discomfort (30)

    Amyotrophic lateral sclerosis (29)

    Neuralgic amyotrophy (29)

    Postictal state (29)

    Pyramidal tract syndrome (29)

    Peroneal nerve palsy (28)

    Cerebral ischaemia (27)

    Fontanelle bulging (27)

    Paraparesis (27)

    Paraplegia (27)

    Dysgraphia (26)

    Quadriplegia (26)

    Sensorimotor disorder (26)

    Tonic clonic movements (26)

    Language disorder (25)

    Decreased vibratory sense (24)

    Monoparesis (24)

    Psychomotor skills impaired (24)

    Sedation (24)

    Brain injury (23)

    Hydrocephalus (23)

    Poor sucking reflex (23)

    Neonatal seizure (22)

    Autonomic nervous system imbalance (21)

    Cerebral infarction (21)

    Cerebrovascular disorder (21)

    Radiculitis brachial (20)

    		 Partial seizures (19)

    Quadriparesis (19)

    IIIrd nerve paralysis (18)

    Clonic convulsion (17)

    Dizziness postural (17)

    Haemorrhage intracranial (17)

    Lhermitte’s sign (17)

    Relapsing-remitting multiple sclerosis (17)

    Restless legs syndrome (17)

    Dysmetria (16)

    Incoherent (16)

    Sciatica (16)

    Cerebral disorder (15)

    Neuromyelitis optica spectrum disorder (15)

    Apraxia (14)

    Brain stem syndrome (14)

    Dementia (14)

    Parosmia (14)

    Reflexes abnormal (14)

    Taste disorder (14)

    Central nervous system inflammation (13)

    Tongue paralysis (13)

    White matter lesion (13)

    Head titubation (12)

    VIth nerve paralysis (12)

    Brachial plexopathy (11)

    Complex regional pain syndrome (11)

    Exaggerated startle response (11)

    Muscle tone disorder (11)

    Subarachnoid haemorrhage (11)

    Chronic inflammatory demyelinating polyradiculoneuropathy (10)

    Demyelinating polyneuropathy (10)

    Diplegia (10)

    Gait spastic (10)

    Hypoxic-ischaemic encephalopathy (10)

    Lower motor neurone lesion (10)

    Slow response to stimuli (10)

    Upper motor neurone lesion (10)

    Cerebral atrophy (9)

    Gross motor delay (9)

    Hemianopia (9)

    IIIrd nerve paresis (9)

    Intracranial aneurysm (9)

    Parkinsonism (9)

    Anosmia (8)

    Cluster headache (8)

    Fine motor delay (8)

    Fontanelle depressed (8)

    Noninfective encephalitis (8)

    Sinus headache (8)

    Spinal cord disorder (8)

    Transient ischaemic attack (8)

    Trigeminal neuralgia (8)

    Tunnel vision (8)

    Consciousness fluctuating (7)

    Cranial nerve disorder (7)

    Fine motor skill dysfunction (7)

    Focal dyscognitive seizures (7)

    Loss of proprioception (7)

    Motor developmental delay (7)

    Myasthenia gravis (7)

    Narcolepsy (7)

    Tension headache (7)

    Tongue biting (7)

    Allodynia (6)

    Amnestic disorder (6)

    Inability to crawl (6)

    Nerve compression (6)

    Paraesthesia mucosal (6)

    Parkinson’s disease (6)

    Peripheral sensory neuropathy (6)

    Progressive multiple sclerosis (6)

    Reduced facial expression (6)

    Akathisia (5)

    Central nervous system vasculitis (5)

    Choreoathetosis (5)

    Encephalitis post immunisation (5)

    Facial neuralgia (5)

    IIIrd nerve disorder (5)

    Neurotoxicity (5)

    Peripheral sensorimotor neuropathy (5)

    Small fibre neuropathy (5)

    Tardive dyskinesia (5)

    Vocal cord paralysis (5)

    Akinesia (4)

    Anaesthesia (4)

    Aura (4)

    Cerebral thrombosis (4)

    Cervicobrachial syndrome (4)

    Convulsions local (4)

    Dyspraxia (4)

    Hemiparaesthesia (4)

    Leukoencephalomyelitis (4)

    Motor neurone disease (4)

    Myoclonic epilepsy (4)

    Orthostatic intolerance (4)

    Brain hypoxia (1)

    Brown-Sequard syndrome (1)

    Carotid artery aneurysm (1)

    Carotid sinus syndrome (1)

    Cerebellar haemorrhage (1)

    Cerebellar infarction (1)

    Cerebral circulatory failure (1)

    Cerebral microhaemorrhage (1)

    Cerebral venous thrombosis (1)

    Cervicogenic headache (1)

    Circadian rhythm sleep disorder (1)

    Cogwheel rigidity (1)

    Cold-stimulus headache (1)

    Dizziness exertional (1)

    Dreamy state (1)

    Dyskinesia neonatal (1)

    Encephalitis haemorrhagic (1)

    Encephalomalacia (1)

    Encephalopathy neonatal (1)

    Essential tremor (1)

    Febrile infection-related epilepsy syndrome (1)

    Fumbling (1)

    Grimacing (1)

    Haemorrhagic stroke (1)

    Hemiplegic migraine (1)

    Hyperpathia (1)

    Hypertensive encephalopathy (1)

    Hypogeusia (1)

    Irregular sleep wake rhythm disorder (1)

    Juvenile myoclonic epilepsy (1)

    Lateral medullary syndrome (1)

    Lennox-Gastaut syndrome (1)

    Lenticulostriatal vasculopathy (1)

    Meralgia paraesthetica (1)

    Metabolic encephalopathy (1)

    		 Migraine without aura (1)

    Mononeuropathy (1)

    Mononeuropathy multiplex (1)

    Nerve degeneration (1)

    Neuroleptic malignant syndrome (1)

    Pachymeningitis (1)

    Palmomental reflex (1)

    Perineurial cyst (1)

    Periodic limb movement disorder (1)

    Peripheral nerve palsy (1)

    Periventricular leukomalacia (1)

    Peripheral nerve lesion (4)

    Radial nerve palsy (4)

    Repetitive speech (4)

    Arachnoiditis (3)

    Asterixis (3)

    Atonic seizures (3)

    Bulbar palsy (3)

    Cauda equina syndrome (3)

    Central pain syndrome (3)

    Cerebral haematoma (3)

    Cerebral hypoperfusion (3)

    Cerebral venous sinus thrombosis (3)

    Cervical radiculopathy (3)

    Chorea (3)

    Developmental coordination disorder (3)

    Diabetic coma (3)

    Drop attacks (3)

    Dyslexia (3)

    Facial nerve disorder (3)

    Gulf war syndrome (3)

    Hand-eye coordination impaired (3)

    Hemianaesthesia (3)

    Hepatic encephalopathy (3)

    Idiopathic intracranial hypertension (3)

    Intention tremor (3)

    Ischaemic stroke (3)

    Leukoencephalopathy (3)

    Migraine with aura (3)

    Miller Fisher syndrome (3)

    Mononeuritis (3)

    Neurosarcoidosis (3)

    Peripheral motor neuropathy (3)

    Radicular pain (3)

    Sciatic nerve palsy (3)

    Sensory integrative dysfunction (3)

    Slow speech (3)

    Temporal lobe epilepsy (3)

    Vascular headache (3)

    Acute polyneuropathy (2)

    Agnosia (2)

    Amimia (2)

    Apallic syndrome (2)

    Burning sensation mucosal (2)

    Cataplexy (2)

    Central auditory processing disorder (2)

    Cerebellar atrophy (2)

    Cerebral arteritis (2)

    Cerebral cyst (2)

    Cholinergic syndrome (2)

    Clinically isolated syndrome (2)

    Convulsion in childhood (2)

    Cranial nerve paralysis (2)

    Encephalitis autoimmune (2)

    Epileptic encephalopathy (2)

    Gliosis (2)

    Hoffmann’s sign (2)

    Intercostal neuralgia (2)

    Intraventricular haemorrhage (2)

    Intraventricular haemorrhage neonatal (2)

    Judgement impaired (2)

    Lumbar radiculopathy (2)

    Meige’s syndrome (2)

    Meningeal disorder (2)

    Myotonia (2)

    Neurodegenerative disorder (2)

    Neuromuscular blockade (2)

    Neuromuscular pain (2)

    Neuromyopathy (2)

    Paresis cranial nerve (2)

    Primary progressive multiple sclerosis (2)

    Ruptured cerebral aneurysm (2)

    Seizure anoxic (2)

    Seizure cluster (2)

    Sensory processing disorder (2)

    Subdural hygroma (2)

    Sudden onset of sleep (2)

    Thermohypoaesthesia (2)

    Vertigo CNS origin (2)

    Acquired epileptic aphasia (1)

    Action tremor (1)

    Agitation neonatal (1)

    Alexia (1)

    Angiopathic neuropathy (1)

    Anosognosia (1)

    Arachnoid cyst (1)

    Athetosis (1)

    Atypical benign partial epilepsy (1)

    Auditory nerve disorder (1)

    Autoimmune demyelinating disease (1)

    Autonomic neuropathy (1)

    Axonal neuropathy (1)

    Blood brain barrier defect (1)

    Post herpetic neuralgia (1)

    Posterior reversible encephalopathy syndrome (1)

    Progressive bulbar palsy (1)

    Progressive muscular atrophy (1)

    Progressive relapsing multiple sclerosis (1)

    Pseudoparalysis (1)

    Psychogenic seizure (1)

    Quadrantanopia (1)

    Radial nerve compression (1)

    Relapsing multiple sclerosis (1)

    Retinal migraine (1)

    Secondary progressive multiple sclerosis (1)

    Somnolence neonatal (1)

    Spinal cord haemorrhage (1)

    Spinal cord oedema (1)

    Subdural effusion (1)

    Sydenham’s chorea (1)

    Thalamic infarction (1)

    Thermoanaesthesia (1)

    Toxic encephalopathy (1)

    Toxic neuropathy (1)

    Typical aura without headache (1)

    Uncinate fits (1)

    Vagus nerve disorder (1)

    Visual pathway disorder (1)

    VIth nerve disorder (1)
    Merck has been encouraged to lie to families and obfuscated the causal relationship between both vaccines, by withholding important information resulting in long-term, serious side-effects. Institutions ostensibly set up to protect the health of children have failed miserably in their duties, and in fact, emboldened the irresponsible conduct of the entire vaccine manufacturing sector. This lack of accountability beginning at the heart of the clinical trial process must be addressed immediately, and the major causal role which amorphous aluminum hydroxyphosphate sulfate has in triggering neuro-developmental and neurological injuries cannot be ignored any longer. The science is overwhelming as to a blatant cover-up perpetrated by the CDC, FDA, WHO, global vaccine corporations and our appointed government health agencies. Families are being torn apart and the trust which doctors once may have fostered has been obliterated through decades of lies and deception. The vaccine industry is culpable in destroying the credibility of the medical establishment. Every incident of injury compiled here-in represents a mere snapshot of tens of thousands of similar episodes unfolding in clinics and hospitals every day around the world. At what point are we going to put a stop to this institutionalized form of assault, to protect our children from further harm?
    Keep Them From Harm is an extensive investigative report which uncovers the apparatus behind vaccines, a ground-breaking exposé ten years in the making. This essential book is available now. 

  • Comments are closed.


<ul><li><strong>woo_cat_nav_107</strong> - false</li><li><strong>woo_cat_nav_141</strong> - false</li><li><strong>woo_cat_nav_142</strong> - false</li><li><strong>woo_cat_nav_126</strong> - false</li><li><strong>woo_cat_nav_177</strong> - false</li><li><strong>woo_cat_nav_138</strong> - false</li><li><strong>woo_cat_nav_109</strong> - false</li><li><strong>woo_cat_nav_172</strong> - false</li><li><strong>woo_cat_nav_169</strong> - false</li><li><strong>woo_cat_nav_160</strong> - false</li><li><strong>woo_cat_nav_131</strong> - false</li><li><strong>woo_cat_nav_162</strong> - false</li><li><strong>woo_cat_nav_137</strong> - false</li><li><strong>woo_cat_nav_174</strong> - false</li><li><strong>woo_cat_nav_171</strong> - false</li><li><strong>woo_cat_nav_144</strong> - false</li><li><strong>woo_cat_nav_173</strong> - false</li><li><strong>woo_cat_nav_136</strong> - false</li><li><strong>woo_cat_nav_178</strong> - false</li><li><strong>woo_cat_nav_165</strong> - false</li><li><strong>woo_cat_nav_106</strong> - false</li><li><strong>woo_cat_nav_127</strong> - false</li><li><strong>woo_cat_nav_176</strong> - false</li><li><strong>woo_cat_nav_135</strong> - false</li><li><strong>woo_cat_nav_175</strong> - false</li><li><strong>woo_cat_color_107</strong> - </li><li><strong>woo_cat_color_141</strong> - </li><li><strong>woo_cat_color_142</strong> - </li><li><strong>woo_cat_color_126</strong> - </li><li><strong>woo_cat_color_177</strong> - </li><li><strong>woo_cat_color_138</strong> - </li><li><strong>woo_cat_color_109</strong> - </li><li><strong>woo_cat_color_172</strong> - </li><li><strong>woo_cat_color_169</strong> - </li><li><strong>woo_cat_color_160</strong> - </li><li><strong>woo_cat_color_131</strong> - </li><li><strong>woo_cat_color_162</strong> - </li><li><strong>woo_cat_color_137</strong> - </li><li><strong>woo_cat_color_174</strong> - </li><li><strong>woo_cat_color_171</strong> - </li><li><strong>woo_cat_color_144</strong> - </li><li><strong>woo_cat_color_173</strong> - </li><li><strong>woo_cat_color_136</strong> - </li><li><strong>woo_cat_color_178</strong> - </li><li><strong>woo_cat_color_165</strong> - </li><li><strong>woo_cat_color_106</strong> - </li><li><strong>woo_cat_color_127</strong> - </li><li><strong>woo_cat_color_176</strong> - </li><li><strong>woo_cat_color_135</strong> - </li><li><strong>woo_cat_color_175</strong> - </li><li><strong>woo_cat_nav_59</strong> - true</li><li><strong>woo_cat_nav_64</strong> - true</li><li><strong>woo_cat_nav_65</strong> - true</li><li><strong>woo_cat_nav_70</strong> - true</li><li><strong>woo_cat_nav_66</strong> - false</li><li><strong>woo_cat_nav_60</strong> - false</li><li><strong>woo_cat_nav_62</strong> - true</li><li><strong>woo_cat_nav_71</strong> - true</li><li><strong>woo_cat_nav_63</strong> - false</li><li><strong>woo_cat_nav_67</strong> - true</li><li><strong>woo_cat_nav_68</strong> - false</li><li><strong>woo_cat_nav_69</strong> - true</li><li><strong>woo_cat_nav_61</strong> - true</li><li><strong>woo_cat_color_59</strong> - </li><li><strong>woo_cat_color_64</strong> - </li><li><strong>woo_cat_color_65</strong> - </li><li><strong>woo_cat_color_70</strong> - </li><li><strong>woo_cat_color_66</strong> - </li><li><strong>woo_cat_color_60</strong> - </li><li><strong>woo_cat_color_62</strong> - </li><li><strong>woo_cat_color_71</strong> - </li><li><strong>woo_cat_color_63</strong> - </li><li><strong>woo_cat_color_67</strong> - </li><li><strong>woo_cat_color_68</strong> - </li><li><strong>woo_cat_color_69</strong> - </li><li><strong>woo_cat_color_61</strong> - </li><li><strong>woo_cat_nav_81</strong> - true</li><li><strong>woo_cat_nav_82</strong> - true</li><li><strong>woo_cat_nav_83</strong> - true</li><li><strong>woo_post_size</strong> - false</li><li><strong>woo_themename</strong> - myweblog</li><li><strong>woo_shortname</strong> - woo</li><li><strong>woo_manual</strong> - http://www.woothemes.com/support/theme-documentation/wootheme/</li><li><strong>woo_single_thumb</strong> - true</li><li><strong>woo_alt_stylesheet</strong> - default.css</li><li><strong>woo_logo</strong> - </li><li><strong>woo_custom_favicon</strong> - </li><li><strong>woo_google_analytics</strong> - <script type=\"text/javascript\">
var gaJsHost = ((\"https:\" == document.location.protocol) ? \"https://ssl.\" : \"http://www.\");
document.write(unescape(\"%3Cscript src=\'\" + gaJsHost + \"google-analytics.com/ga.js\' type=\'text/javascript\'%3E%3C/script%3E\"));
</script>
<script type=\"text/javascript\">
try {
var pageTracker = _gat._getTracker(\"UA-13204227-1\");
pageTracker._trackPageview();
} catch(err) {}</script></li><li><strong>woo_feedburner_url</strong> - </li><li><strong>woo_custom_css</strong> - </li><li><strong>woo_resize</strong> - false</li><li><strong>woo_auto_img</strong> - false</li><li><strong>woo_cat_nav_3</strong> - true</li><li><strong>woo_cat_nav_1</strong> - true</li><li><strong>woo_cat_color_3</strong> - </li><li><strong>woo_cat_color_1</strong> - </li><li><strong>woo_ad_footer</strong> - false</li><li><strong>woo_ad_footer_adsense</strong> - </li><li><strong>woo_ad_footer_image</strong> - http://vaccineresistancemovement.org/wp-content/woo_uploads/4-3-banner-oxysilver.jpg</li><li><strong>woo_ad_footer_url</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_img_1</strong> - http://www.woothemes.com/ads/woothemes-125x125-1.gif</li><li><strong>woo_sidebar_ad_href_1</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_img_2</strong> - http://www.woothemes.com/ads/woothemes-125x125-2.gif</li><li><strong>woo_sidebar_ad_href_2</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_img_3</strong> - http://www.woothemes.com/ads/woothemes-125x125-3.gif</li><li><strong>woo_sidebar_ad_href_3</strong> - http://www.woothemes.com</li><li><strong>woo_sidebar_ad_img_4</strong> - http://www.woothemes.com/ads/woothemes-125x125-4.gif</li><li><strong>woo_sidebar_ad_href_4</strong> - http://www.woothemes.com</li><li><strong>woo_cat_nav_55</strong> - true</li><li><strong>woo_cat_nav_49</strong> - true</li><li><strong>woo_cat_nav_41</strong> - true</li><li><strong>woo_cat_nav_39</strong> - true</li><li><strong>woo_cat_color_46</strong> - </li><li><strong>woo_cat_color_40</strong> - </li><li><strong>woo_cat_color_42</strong> - </li><li><strong>woo_cat_color_51</strong> - </li><li><strong>woo_cat_color_35</strong> - </li><li><strong>woo_cat_color_32</strong> - </li><li><strong>woo_cat_color_37</strong> - </li><li><strong>woo_cat_color_38</strong> - </li><li><strong>woo_cat_color_52</strong> - </li><li><strong>woo_cat_color_50</strong> - </li><li><strong>woo_cat_color_49</strong> - </li><li><strong>woo_cat_color_41</strong> - </li><li><strong>woo_cat_color_39</strong> - </li><li><strong>woo_cat_nav_23</strong> - true</li><li><strong>woo_cat_nav_4</strong> - false</li><li><strong>woo_cat_nav_28</strong> - false</li><li><strong>woo_cat_nav_5</strong> - true</li><li><strong>woo_cat_nav_27</strong> - true</li><li><strong>woo_cat_nav_6</strong> - true</li><li><strong>woo_cat_nav_7</strong> - true</li><li><strong>woo_cat_nav_24</strong> - false</li><li><strong>woo_cat_nav_8</strong> - true</li><li><strong>woo_cat_nav_9</strong> - true</li><li><strong>woo_cat_nav_10</strong> - true</li><li><strong>woo_cat_nav_11</strong> - true</li><li><strong>woo_cat_nav_30</strong> - true</li><li><strong>woo_cat_nav_12</strong> - true</li><li><strong>woo_cat_nav_25</strong> - true</li><li><strong>woo_cat_nav_13</strong> - true</li><li><strong>woo_cat_nav_14</strong> - true</li><li><strong>woo_cat_nav_15</strong> - true</li><li><strong>woo_cat_nav_26</strong> - true</li><li><strong>woo_cat_nav_16</strong> - false</li><li><strong>woo_cat_nav_17</strong> - true</li><li><strong>woo_cat_nav_29</strong> - true</li><li><strong>woo_cat_nav_18</strong> - true</li><li><strong>woo_cat_nav_19</strong> - true</li><li><strong>woo_cat_nav_20</strong> - false</li><li><strong>woo_cat_nav_21</strong> - true</li><li><strong>woo_cat_nav_22</strong> - true</li><li><strong>woo_cat_nav_31</strong> - true</li><li><strong>woo_cat_color_23</strong> - </li><li><strong>woo_cat_color_4</strong> - </li><li><strong>woo_cat_color_28</strong> - 03246B</li><li><strong>woo_cat_color_5</strong> - </li><li><strong>woo_cat_color_27</strong> - </li><li><strong>woo_cat_color_6</strong> - </li><li><strong>woo_cat_color_7</strong> - </li><li><strong>woo_cat_color_24</strong> - </li><li><strong>woo_cat_color_8</strong> - </li><li><strong>woo_cat_color_9</strong> - </li><li><strong>woo_cat_color_10</strong> - </li><li><strong>woo_cat_color_11</strong> - </li><li><strong>woo_cat_color_30</strong> - </li><li><strong>woo_cat_color_12</strong> - </li><li><strong>woo_cat_color_25</strong> - </li><li><strong>woo_cat_color_13</strong> - </li><li><strong>woo_cat_color_14</strong> - </li><li><strong>woo_cat_color_15</strong> - </li><li><strong>woo_cat_color_26</strong> - </li><li><strong>woo_cat_color_16</strong> - </li><li><strong>woo_cat_color_17</strong> - </li><li><strong>woo_cat_color_29</strong> - </li><li><strong>woo_cat_color_18</strong> - </li><li><strong>woo_cat_color_19</strong> - </li><li><strong>woo_cat_color_20</strong> - </li><li><strong>woo_cat_color_21</strong> - </li><li><strong>woo_cat_color_22</strong> - </li><li><strong>woo_cat_color_31</strong> - </li><li><strong>woo_cat_nav_233</strong> - false</li><li><strong>woo_cat_nav_222</strong> - false</li><li><strong>woo_cat_nav_46</strong> - false</li><li><strong>woo_cat_nav_40</strong> - true</li><li><strong>woo_cat_nav_42</strong> - true</li><li><strong>woo_cat_nav_51</strong> - true</li><li><strong>woo_cat_nav_35</strong> - true</li><li><strong>woo_cat_nav_32</strong> - true</li><li><strong>woo_cat_nav_37</strong> - true</li><li><strong>woo_cat_nav_38</strong> - true</li><li><strong>woo_cat_nav_52</strong> - true</li><li><strong>woo_cat_nav_50</strong> - false</li><li><strong>woo_cat_nav_53</strong> - true</li><li><strong>woo_cat_nav_54</strong> - true</li><li><strong>woo_cat_nav_56</strong> - true</li><li><strong>woo_cat_nav_57</strong> - true</li><li><strong>woo_cat_color_55</strong> - </li><li><strong>woo_cat_color_53</strong> - </li><li><strong>woo_cat_color_54</strong> - </li><li><strong>woo_cat_color_56</strong> - </li><li><strong>woo_cat_color_57</strong> - </li><li><strong>woo_uploads</strong> - a:2:{i:0;s:84:"http://vaccineresistancemovement.org/wp-content/woo_uploads/4-3-banner-oxysilver.jpg";i:1;s:82:"http://vaccineresistancemovement.org/wp-content/woo_uploads/3-banner-oxysilver.jpg";}</li><li><strong>woo_cat_nav_58</strong> - false</li><li><strong>woo_cat_color_58</strong> - </li><li><strong>woo_cat_nav_80</strong> - true</li><li><strong>woo_cat_nav_78</strong> - true</li><li><strong>woo_cat_nav_73</strong> - true</li><li><strong>woo_cat_nav_74</strong> - true</li><li><strong>woo_cat_nav_72</strong> - true</li><li><strong>woo_cat_nav_79</strong> - true</li><li><strong>woo_cat_nav_76</strong> - true</li><li><strong>woo_cat_nav_75</strong> - true</li><li><strong>woo_cat_nav_77</strong> - true</li><li><strong>woo_cat_color_81</strong> - </li><li><strong>woo_cat_color_82</strong> - </li><li><strong>woo_cat_color_83</strong> - </li><li><strong>woo_cat_color_80</strong> - </li><li><strong>woo_cat_color_78</strong> - </li><li><strong>woo_cat_color_73</strong> - </li><li><strong>woo_cat_color_74</strong> - </li><li><strong>woo_cat_color_72</strong> - </li><li><strong>woo_cat_color_79</strong> - 2F83DE</li><li><strong>woo_cat_color_76</strong> - </li><li><strong>woo_cat_color_75</strong> - </li><li><strong>woo_cat_color_77</strong> - </li><li><strong>woo_cat_nav_98</strong> - true</li><li><strong>woo_cat_nav_104</strong> - true</li><li><strong>woo_cat_nav_99</strong> - true</li><li><strong>woo_cat_nav_101</strong> - true</li><li><strong>woo_cat_nav_95</strong> - true</li><li><strong>woo_cat_nav_102</strong> - true</li><li><strong>woo_cat_nav_105</strong> - true</li><li><strong>woo_cat_nav_100</strong> - false</li><li><strong>woo_cat_nav_103</strong> - true</li><li><strong>woo_cat_nav_96</strong> - true</li><li><strong>woo_cat_nav_97</strong> - true</li><li><strong>woo_cat_nav_85</strong> - true</li><li><strong>woo_cat_nav_91</strong> - true</li><li><strong>woo_cat_nav_93</strong> - true</li><li><strong>woo_cat_nav_92</strong> - true</li><li><strong>woo_cat_nav_89</strong> - true</li><li><strong>woo_cat_nav_90</strong> - true</li><li><strong>woo_cat_nav_88</strong> - true</li><li><strong>woo_cat_nav_87</strong> - true</li><li><strong>woo_cat_nav_94</strong> - true</li><li><strong>woo_cat_nav_86</strong> - true</li><li><strong>woo_cat_nav_84</strong> - false</li><li><strong>woo_cat_color_98</strong> - </li><li><strong>woo_cat_color_104</strong> - </li><li><strong>woo_cat_color_99</strong> - </li><li><strong>woo_cat_color_101</strong> - </li><li><strong>woo_cat_color_95</strong> - </li><li><strong>woo_cat_color_102</strong> - </li><li><strong>woo_cat_color_105</strong> - </li><li><strong>woo_cat_color_100</strong> - </li><li><strong>woo_cat_color_103</strong> - </li><li><strong>woo_cat_color_96</strong> - </li><li><strong>woo_cat_color_97</strong> - </li><li><strong>woo_cat_color_85</strong> - </li><li><strong>woo_cat_color_91</strong> - </li><li><strong>woo_cat_color_93</strong> - </li><li><strong>woo_cat_color_92</strong> - </li><li><strong>woo_cat_color_89</strong> - </li><li><strong>woo_cat_color_90</strong> - </li><li><strong>woo_cat_color_88</strong> - </li><li><strong>woo_cat_color_87</strong> - </li><li><strong>woo_cat_color_94</strong> - </li><li><strong>woo_cat_color_86</strong> - </li><li><strong>woo_cat_color_84</strong> - </li><li><strong>woo_cat_nav_219</strong> - false</li><li><strong>woo_cat_nav_230</strong> - false</li><li><strong>woo_cat_nav_192</strong> - false</li><li><strong>woo_cat_nav_224</strong> - false</li><li><strong>woo_cat_nav_215</strong> - false</li><li><strong>woo_cat_nav_193</strong> - false</li><li><strong>woo_cat_nav_202</strong> - false</li><li><strong>woo_cat_nav_211</strong> - false</li><li><strong>woo_cat_nav_235</strong> - false</li><li><strong>woo_cat_nav_208</strong> - false</li><li><strong>woo_cat_nav_209</strong> - false</li><li><strong>woo_cat_nav_204</strong> - false</li><li><strong>woo_cat_nav_180</strong> - false</li><li><strong>woo_cat_nav_200</strong> - false</li><li><strong>woo_cat_nav_186</strong> - false</li><li><strong>woo_cat_nav_187</strong> - false</li><li><strong>woo_cat_nav_190</strong> - false</li><li><strong>woo_cat_nav_205</strong> - false</li><li><strong>woo_cat_nav_229</strong> - false</li><li><strong>woo_cat_nav_197</strong> - false</li><li><strong>woo_cat_nav_189</strong> - false</li><li><strong>woo_cat_nav_206</strong> - false</li><li><strong>woo_cat_nav_212</strong> - false</li><li><strong>woo_cat_nav_213</strong> - false</li><li><strong>woo_cat_nav_214</strong> - false</li><li><strong>woo_cat_nav_218</strong> - false</li><li><strong>woo_cat_nav_226</strong> - false</li><li><strong>woo_cat_nav_181</strong> - false</li><li><strong>woo_cat_nav_196</strong> - false</li><li><strong>woo_cat_nav_184</strong> - false</li><li><strong>woo_cat_nav_194</strong> - false</li><li><strong>woo_cat_nav_234</strong> - false</li><li><strong>woo_cat_nav_228</strong> - false</li><li><strong>woo_cat_nav_221</strong> - false</li><li><strong>woo_cat_nav_220</strong> - false</li><li><strong>woo_cat_color_235</strong> - </li><li><strong>woo_cat_color_208</strong> - </li><li><strong>woo_cat_color_209</strong> - </li><li><strong>woo_cat_color_204</strong> - </li><li><strong>woo_cat_color_180</strong> - </li><li><strong>woo_cat_color_200</strong> - </li><li><strong>woo_cat_color_186</strong> - </li><li><strong>woo_cat_color_187</strong> - </li><li><strong>woo_cat_color_190</strong> - </li><li><strong>woo_cat_color_205</strong> - </li><li><strong>woo_cat_color_229</strong> - </li><li><strong>woo_cat_color_197</strong> - </li><li><strong>woo_cat_color_189</strong> - </li><li><strong>woo_cat_color_206</strong> - </li><li><strong>woo_cat_color_210</strong> - </li><li><strong>woo_cat_color_231</strong> - </li><li><strong>woo_cat_color_191</strong> - </li><li><strong>woo_cat_color_201</strong> - </li><li><strong>woo_cat_color_179</strong> - </li><li><strong>woo_cat_color_198</strong> - </li><li><strong>woo_cat_color_199</strong> - </li><li><strong>woo_cat_color_207</strong> - </li><li><strong>woo_cat_color_223</strong> - </li><li><strong>woo_cat_color_227</strong> - </li><li><strong>woo_cat_color_203</strong> - </li><li><strong>woo_cat_color_188</strong> - </li><li><strong>woo_cat_color_183</strong> - </li><li><strong>woo_cat_color_232</strong> - </li><li><strong>woo_cat_color_185</strong> - </li><li><strong>woo_cat_color_217</strong> - </li><li><strong>woo_cat_color_216</strong> - </li><li><strong>woo_cat_color_225</strong> - </li><li><strong>woo_cat_color_233</strong> - </li><li><strong>woo_cat_color_222</strong> - </li><li><strong>woo_cat_color_219</strong> - </li><li><strong>woo_cat_color_230</strong> - </li><li><strong>woo_cat_color_192</strong> - </li><li><strong>woo_cat_color_224</strong> - </li><li><strong>woo_cat_color_215</strong> - </li><li><strong>woo_cat_color_193</strong> - </li><li><strong>woo_cat_color_202</strong> - </li><li><strong>woo_cat_color_211</strong> - </li><li><strong>woo_cat_color_212</strong> - </li><li><strong>woo_cat_color_213</strong> - </li><li><strong>woo_cat_color_214</strong> - </li><li><strong>woo_cat_color_218</strong> - </li><li><strong>woo_cat_color_226</strong> - </li><li><strong>woo_cat_color_181</strong> - </li><li><strong>woo_cat_color_196</strong> - </li><li><strong>woo_cat_color_184</strong> - </li><li><strong>woo_cat_color_194</strong> - </li><li><strong>woo_cat_color_234</strong> - </li><li><strong>woo_cat_color_228</strong> - </li><li><strong>woo_cat_color_221</strong> - </li><li><strong>woo_cat_color_220</strong> - </li><li><strong>woo_cat_nav_210</strong> - false</li><li><strong>woo_cat_nav_231</strong> - false</li><li><strong>woo_cat_nav_191</strong> - false</li><li><strong>woo_cat_nav_201</strong> - false</li><li><strong>woo_cat_nav_179</strong> - false</li><li><strong>woo_cat_nav_198</strong> - false</li><li><strong>woo_cat_nav_199</strong> - false</li><li><strong>woo_cat_nav_207</strong> - false</li><li><strong>woo_cat_nav_223</strong> - false</li><li><strong>woo_cat_nav_227</strong> - false</li><li><strong>woo_cat_nav_203</strong> - false</li><li><strong>woo_cat_nav_188</strong> - false</li><li><strong>woo_cat_nav_183</strong> - false</li><li><strong>woo_cat_nav_232</strong> - false</li><li><strong>woo_cat_nav_185</strong> - false</li><li><strong>woo_cat_nav_217</strong> - false</li><li><strong>woo_cat_nav_216</strong> - false</li><li><strong>woo_cat_nav_225</strong> - false</li></ul>